Sugi Predict

Sugi Predict / Compounds / SCHEMBL19687073

SCHEMBL19687073

SCHEMBL19687073

Cc1ccn(-c2cc(NC3CCC(F)(F)CC3)cc(N3CCOCC3)n2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 2/20 0.38
▸ RAF1 P04049 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CRHBP P24387 2/20 0.36
▸ CRHR2 Q13324 2/20 0.36
▸ SMN1; SMN2 Q16637 5/20 0.35
▸ MAPT P10636 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ HTT P42858 2/20 0.35
▸ PKM P14618 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PIK3CB P42338 1/20 0.35
▸ GBA1 P04062 1/20 0.35
▸ EHMT2 Q96KQ7 1/20 0.35
▸ EHMT1 Q9H9B1 1/20 0.35
▸ SCD O00767 1/20 0.35
▸ LRRK2 Q5S007 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19687334 0.90 IDH1 (0.44) IDH1RAF1KMT2ACRHBPCRHR2
SCHEMBL19687114 0.84 IDH1 (0.37) IDH1MAPTLRRK2HRH4TP53
Rimtuzalcap SCHEMBL29920754 0.84 IDH1 (0.43) IDH1KMT2ASMN1; SMN2MAPTHTT
Rimtuzalcap SCHEMBL19686931 0.84 IDH1 (0.43) IDH1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL19686421 0.83 IDH1 (0.41) IDH1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL19686450 0.83 SMN1; SMN2 (0.50) RAF1KMT2ACRHBPCRHR2SMN1; SMN2
SCHEMBL31127166 0.82 IDH1 (0.41) IDH1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL21143856 0.82 IDH1 (0.41) IDH1SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL21165843 0.81 IDH1 (0.42) IDH1KMT2AMAPTHPGDHRH4
SCHEMBL19686364 0.81 IDH1 (0.47) IDH1KMT2ASMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 — — US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 — — US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 — — US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 — — US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 — — US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885RAF1 470/4885KMT2A 1471/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885RAF1 470/4885KMT2A 1471/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885RAF1 470/4885KMT2A 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.